Nutritional Support of the Neonate: Alternate Fuels and Routes of Administration

1991 ◽  
pp. 719-742 ◽  
Author(s):  
Robert M. Kliegman ◽  
Susan Aucott ◽  
Marianne Kosek
Keyword(s):  
Nutritional Support ◽  
Routes Of Administration ◽  
Alternate Fuels

Nutritional Support of the Surgical Oncology Patient

1991 ◽  
Vol 5 (1) ◽  
pp. 125-145 ◽  
Author(s):  
Mike K. Chen ◽  
Wiley W. Souba ◽  
Edward M. Copeland
Keyword(s):  
Nutritional Support ◽  
Surgical Oncology ◽  
Oncology Patient

Extravascular Administration of Factor IX: Potential for Replacement Therapy of Canine and Human Hemophilia B

1997 ◽  
Vol 77 (05) ◽  
pp. 0944-0948 ◽  
Author(s):  
Darla Liles ◽  
Charles N Landen ◽  
Dougald M Monroe ◽  
Celeste M Lindley ◽  
Marjorie s Read ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Vitamin K ◽  
Absorption Rate ◽  
Venous Access ◽  
Factor Ix ◽  
Hemophilia B ◽  
Current Therapy ◽  
Home Therapy ◽  
Routes Of Administration ◽  
Plasma Compartment

SummaryCurrent therapy for hemophilia B requires large intravenous doses of factor IX (F.IX) given in the clinic or at home. Although home therapy is possible for many patients, it is often complicated by factors such as the lack of good venous access. Very little is known about extravascular routes for administering proteins like F.IX (57 kD) or other vitamin K-dependent procoagulant factors into the circulation. Questions about the absorption rate from extravascular administration as well as plasma recovery and bioavailability have arisen recently with the growing availibility of highly purified procoagulant proteins and increased interest in gene therapy of hemophilia B. Therefore, a group of studies were undertaken to determine the absorption rate, plasma recovery, and bioavailability of high purity, human plasma-derived F.IX concentrates administered via extravascular routes in hemophilia B dogs and in one human hemophilia B subject. Five hemophilia B dogs were given human F.IX via either a subcutaneous (SC), intramuscular (IM), intra- peritoneal (IP) or intravenous (IV) route. In a subsequent study, a single SC administration of human F.IX was compared to an identical IV dose of F.IX in the human hemophilia B subject. All extravascular routes of F.IX administration in both the canine and human gave lower levels of circulating plasma F.IX than the IV route, however all routes resulted in measurable F.IX activity. Of the extravascular routes, the IM injection in the canine resulted in a bioavailibility of 82.8%, while the SC injection resulted in a bioavailability of 63.5%. F.IX reached the plasma compartment by all extravascular routes used, confirming that F.IX can be absorbed extravascularly. The duration of measurable F.IX activity following extravascular administration is prolonged beyond that typically seen with IV administration. These data show that significant levels of F.IX may be obtained via SC injection in canine and ‘ human hemophilia B subjects and further highlight the potential of extravascular routes of administration for future experimental and clinical uses of F.IX and other procoagulant proteins.

Comparative Study of Intranasal, Subcutaneous and Intravenous Administration of Desamino-D-Arginine Vasopressin (DDAVP)

1986 ◽  
Vol 55 (01) ◽  
pp. 108-111 ◽  
Author(s):  
M Köhler ◽  
P Hellstern ◽  
C Miyashita ◽  
G von Blohn ◽  
E Wenzel
Keyword(s):  
Factor Viii ◽  
Von Willebrand Factor ◽  
Factor Xii ◽  
Additional Advantage ◽  
Mean Values ◽  
Routes Of Administration ◽  
The Mean ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
Factor Antigen

SummaryThis study was performed to evaluate the influence of different routes of administration on the efficacy of DDAVP treatment. Ten healthy volunteers received DDAVP intranasally (i.n.), subcutaneously (s.c.) and intravenously (i.v.) in a randomized cross-over trial. Factor XII and high molecular weight (HMW)-kininogen levels increased only slightly after DDAVP administration. The mean increase of factor VIII: C was 3.1 (i. v.), 2.3 (s. c.), and 1.3 (i.n.) - fold over baseline. Ristocetin cofactor (von Willebrand factor antigen) increased 3.1 (2.5), 2.0 (2.3) and 1.2 (1.2) - fold over baseline mean values after i.v., s.c. and i.n. DDAVP, respectively. The half-disappearance time of factor VIII and von Willebrand factor (vWF) after DDAVP ranged from five (factor VIII: C) to eight hours (vWF). The mean increase of fibrinolytic activity was more pronounced after i.v. DDAVP. The antidiuretic effect was moderate with no apparent differences between the routes of application. This study provides further evidence that both i.v. and s.c. DDAVP administration result in an appropriate and reliable stimulation of haemostasis. An additional advantage of s. c. administration is its suitability for home treatment.

Place of progestogenic oral contraceptives in gynecological practice

2019 ◽  
Vol 1 (1) ◽  
pp. 19-26
Author(s):  
I. V. Kuznetsova
Keyword(s):  
Venous Thrombosis ◽  
Oral Contraceptives ◽  
Hormonal Contraception ◽  
Review Of The Literature ◽  
Safety Issues ◽  
Routes Of Administration ◽  
Positive Effects ◽  
Combined Hormonal Contraception

The review of the literature presents data on the possible risks of using combined hormonal contraception and the possibilities of prescribing purely progestogenic contraception as an alternative to the use of combined means. Progestogen contraceptives include a group of agents with different routes of administration, doses and characteristics of progestins, which have a number of differences in the ratio of benefits and risks, availability, reversibility and other properties of contraception. Particular attention is paid to purely progestogenic tablets containing desogestrel, as a means equivalent in effectiveness to combination contraceptives, but safer. Safety issues are considered in the context of the use of breastfeeding women, as well as from the standpoint of the risk of arterial and venous thrombosis. The issues of non-contraceptive positive effects of purely progestogenic contraceptives are covered.

Pharmaconutrition: pharmacological approach to nutrition therapy

2014 ◽  
Vol 155 (51) ◽  
pp. 2021-2027
Author(s):  
István Télessy
Keyword(s):  
Fatty Acids ◽  
Nutritional Support ◽  
Pharmacological Action ◽  
Nutrition Therapy ◽  
Therapeutic Agents ◽  
Therapeutic Action ◽  
Treatment Results ◽  
Research Activity ◽  
Therapeutic Modalities ◽  
The Everyday

Reviewing the literature of nutrition therapy one can conclude that during the last decade the pharmacological action of several nutrients has been demonstrated. However, research activity is still at the beginning and it could be verified in a restricted number of nutrients only that in which conditions (illnesses), dose and duration we can expect therapeutic effect in addition to nutrition. The examples of glutamine, arginine, taurine, leucine, ω-3 fatty acids, however, support the possibility that complex reactions and treatment results observed in certain patients are not purely due to nutritional support but the consequence of additional pharmacological action as well. Evaluation of results of therapeutic intervention is especially difficult because in the everyday practice physicians try to use several therapeutic modalities that can be beneficial for the patient. Therefore, retrospective separation of beneficial components of the therapeutic agents is almost impossible. Only well designed, randomized and multicentric studies can verify specific therapeutic action of certain ingredients ie. nutrients. Orv. Hetil., 2014, 155(51), 2021–2027.

Nutrition as an important component of treatment and rehabilitation in cancer patients

2020 ◽  
pp. 15-22
Author(s):  
T.F. Tatarchuk ◽  
◽  
E.G. Manzhalii ◽  
D.V. Pominchuk ◽  
T.S. Shevchuk ◽  
...  
Keyword(s):  
Cancer Patients ◽  
High Frequency ◽  
Nutritional Support ◽  
Digestive System ◽  
Multidisciplinary Approach ◽  
Dietary Factors ◽  
Protective Activity ◽  
Macro And Micronutrients ◽  
Diet And Lifestyle ◽  
Cachexia Syndrome

The article deals with the importance of nutritional support for cancer patients. The high frequency of malnutrition and impaired absorption of macro and micronutrients in cancer patients and, which, at its maximum, is anorexia-cachexia syndrome, is the direct cause of the patient’s death. The progression of the tumor process is always accompanied by a violation of nutritional status, which is manifested in changes in weight, weakness, decreased physical activity, and disorders of the digestive system. It is estimated that about half of cancer-related deaths can be prevented, many of which are due to diet and lifestyle. Dietary factors can be involved in the initiation of tumor growth (carcinogens), promote growth, or have protective activity against the development of cancer. Therefore, nutritional support is one of the important components of a multidisciplinary approach in the treatment of cancer. Based on the analysis of the literature, the main tasks of nutritional support, indications, methods and criteria for the effectiveness of therapeutic nutrition are determined for the practitioner, a brief overview of the diets that are used by cancer patients is presented, and a list of anticarcinogenic products is compiled. Key words: anticarcinogenic products, diet, nutritional support, cancer patient, cancer prevention, nutrition.

Sign in / Sign up

Export Citation Format

Share Document